Thrombopoietin - Genentech

Drug Profile

Thrombopoietin - Genentech

Alternative Names: Recombinant human thrombopoietin; rhTPO; TPO

Latest Information Update: 22 Oct 2003

Price : $50

At a glance

  • Originator Genentech
  • Class Colony-stimulating factors; Glycoproteins
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombocytopenia

Most Recent Events

  • 22 Oct 2003 Discontinued - Phase-III for Thrombocytopenia in USA (unspecified route)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 31 Jan 2002 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top